Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

201.72 -6.32 (-3.04%)
Streaming Delayed Price Updated: 1:23 PM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 797,459
Open 200.17
Bid (Size) 201.44 (100)
Ask (Size) 201.99 (200)
Prev. Close 208.04
Today's Range 196.22 - 203.91
52wk Range 125.38 - 256.36
Shares Outstanding 139,693,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics. 
Via The Motley Fool
Topics Lawsuit
News headline image
Why Natera (NTRA) Shares Are Falling Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 8.3% in the afternoon session after the release of a key inflation report revealed prices paid to U.S. producers rose more than anticipated... 
Via StockStory
Topics Earnings Economy

Performance

YTD
-11.9%
-11.9%
1 Month
-12.7%
-12.7%
3 Month
-13.9%
-13.9%
6 Month
+19.1%
+19.1%
1 Year
+41.0%
+41.0%

More News

Read More
News headline image
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
From Natera, Inc.
Via Business Wire
News headline image
Natera (NTRA) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Natera Inc. (NASDAQ:NTRA) Crushes Q4 Earnings Estimates with Strong Oncology Growth ↗
Via Chartmill
News headline image
Natera Reports Fourth Quarter and Full Year 2025 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera Earnings: What To Look For From NTRA
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
From Natera, Inc.
Via Business Wire
News headline image
Billionaire Stanley Druckenmiller Is Betting Big on These 2 Stocks ↗
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
From Natera, Inc.
Via Business Wire
News headline image
Natera Submits Signatera™ CDx PMA to FDA
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
From Natera, Inc.
Via Business Wire
News headline image
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
From Natera, Inc.
Via Business Wire
News headline image
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds
Via StockStory
News headline image
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting
From Natera, Inc.
Via Business Wire
News headline image
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth
Via MarketMinute
News headline image
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
Via MarketMinute
News headline image
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
From Natera, Inc.
Via Business Wire
News headline image
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
From Natera, Inc.
Via Business Wire
News headline image
2 Cash-Heavy Stocks to Keep an Eye On and 1 We Question
Via StockStory
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
From Exelixis, Inc.
Via Business Wire

Frequently Asked Questions

Is Natera, Inc. - Common Stock publicly traded?
Yes, Natera, Inc. - Common Stock is publicly traded.
What exchange does Natera, Inc. - Common Stock trade on?
Natera, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Natera, Inc. - Common Stock?
The ticker symbol for Natera, Inc. - Common Stock is NTRA on the Nasdaq Stock Market
What is the current price of Natera, Inc. - Common Stock?
The current price of Natera, Inc. - Common Stock is 201.72
When was Natera, Inc. - Common Stock last traded?
The last trade of Natera, Inc. - Common Stock was at 03/02/26 01:23 PM ET
What is the market capitalization of Natera, Inc. - Common Stock?
The market capitalization of Natera, Inc. - Common Stock is 28.18B
How many shares of Natera, Inc. - Common Stock are outstanding?
Natera, Inc. - Common Stock has 28B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.